The results of the BOLERO-2 trial showed that dual-blockade with EVE–EXE more than doubled median PFS versus EXE alone in patients with hormone receptor-positive (HR+)/human epidermal growth receptor 2-negative (HER2−) metastatic BC recurring/progressing on prior non-steroidal aromatase inhibitors (NSAIs) (7.8 versus 3.2 months) [24,25,26]. This evidence concerns the gene NR4A1 and breast cancer.